Cognition Therapeutics Extends IP Coverage of Alzheimer’s Therapeutic Elayta™ to Additional Major Pharmaceutical Markets with Patent Issuances in Japan and China

PITTSBURGH, July 24 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced the issuance by the Japan Patent Office and China’s National Intellectual Property Administration of composition of matter patents for Elayta™, Cognition’s lead clinical stage …

Cognition Therapeutics Extends IP Coverage of Alzheimer’s Therapeutic Elayta™ to Additional Major Pharmaceutical Markets with Patent Issuances in Japan and China Read More »